Related Experiment Video
Updated: Apr 16, 2026
Ex vivo Expansion of Tumor-reactive T Cells by Means of Bryostatin 1/Ionomycin and the Common Gamma Chain Cytokines Formulation
Published on: January 14, 2011
IL-7Rα signaling potentiates the anti-tumor activity of NK92 cells
Chunli Wang1,2, Seokmin Kim1,3, Ling-Zu Kong1,4
1Center for Gene and Cell Therapy, Korea Research Institute of Bioscience and Biotechnology (KRIBB), Daejeon, Republic of Korea.
Background:
Natural killer (NK) cells are promising candidates for cancer immunotherapy due to their safety and potent anti-tumor activity. However, their therapeutic efficacy is often limited by poor persistence and activity within the tumor microenvironment (TME) caused by a lack of essential cytokines.
Methods:
To overcome cytokine dependence, we engineered NK92, primary NK (pNK), and chimeric antigen receptor (CAR)-NK92 cells to express an interleukin-7 receptor with an insertion mutation (IL-7R-IM), which induces constitutive signaling. We evaluated the proliferation, viability, and cytotoxicity of these cells in vitro and analyzed downstream signaling pathways using RNA sequencing and western blotting. The in vivo anti-tumor efficacy was assessed using a metastatic leukemia xenograft mouse model.
Results:
NK92-IL-7R-IM cells exhibited sustained proliferation and high viability independent of exogenous cytokines, superior to IL-2-activated NK cells. This enhanced functionality was driven by the constitutive activation of the JAK/STAT, AKT, and ERK signaling pathways, leading to the upregulation of cytotoxicity-related genes (GZMA, GZMB) and anti-apoptotic genes (BCL2L1). In vivo, NK92-IL-7R-IM cells demonstrated significantly potent anti-tumor activity and extended survival compared to control groups. Furthermore, the IL-7R-IM strategy successfully enhanced the function of CAR-NK cells targeting EphA2, EGFR, and CD5 antigens.
Conclusions:
The expression of IL-7R-IM confers cytokine independence and robust anti-tumor activity to NK and CAR-NK cells. This strategy offers a practical solution to improve the persistence and efficacy of off-the-shelf NK cell therapeutics for clinical application.
Insights
Engineered natural killer (NK) cells expressing IL-7R-IM show enhanced anti-tumor activity and persistence, overcoming cytokine dependence for improved cancer immunotherapy. This strategy boosts NK cell efficacy in preclinical models.
Area of Science:
- Immunology
- Cell Biology
- Cancer Research
Background:
- Natural killer (NK) cells are potent cancer immunotherapy candidates but face limitations in persistence and activity within the tumor microenvironment (TME) due to cytokine dependency.
- Engineering NK cells to overcome these limitations is crucial for enhancing their therapeutic efficacy in cancer treatment.
Purpose of the Study:
- To engineer NK92, primary NK (pNK), and chimeric antigen receptor (CAR)-NK92 cells to express a constitutively signaling interleukin-7 receptor with an insertion mutation (IL-7R-IM).
- To evaluate the impact of IL-7R-IM expression on NK cell proliferation, viability, cytotoxicity, and in vivo anti-tumor efficacy.
Main Methods:
- Engineered NK cells (NK92, pNK, CAR-NK92) to express IL-7R-IM for constitutive signaling.
- Assessed in vitro proliferation, viability, and cytotoxicity.
- Analyzed downstream signaling pathways (JAK/STAT, AKT, ERK) via RNA sequencing and western blotting.
- Evaluated in vivo anti-tumor efficacy in a metastatic leukemia xenograft mouse model.
Main Results:
- NK92-IL-7R-IM cells demonstrated sustained proliferation and viability independent of external cytokines, outperforming IL-2-activated NK cells.
- Constitutive activation of JAK/STAT, AKT, and ERK pathways led to increased expression of cytotoxicity (GZMA, GZMB) and anti-apoptotic (BCL2L1) genes.
- In vivo studies showed potent anti-tumor activity and extended survival in mice treated with NK92-IL-7R-IM cells.
- The IL-7R-IM strategy enhanced the function of CAR-NK cells targeting EphA2, EGFR, and CD5.
Conclusions:
- IL-7R-IM expression confers cytokine independence and robust anti-tumor activity to NK and CAR-NK cells.
- This approach offers a viable strategy to improve the persistence and efficacy of off-the-shelf NK cell therapeutics for clinical applications.
- The engineered NK cells show promise for overcoming current limitations in NK cell-based cancer immunotherapy.
Related Concept Videos
01:27Cytotoxic T Cells-mediated Immune Response
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
01:27Tumor Immunotherapy
01:28Cells of the Innate Immune Response
Phagocytes
Phagocytes police the peripheral tissues by removing cellular debris and responding to the invasion of foreign substances or pathogens. Many phagocytes attack and remove microorganisms even before lymphocytes detect them. The human body has two general...